<DOC>
	<DOCNO>NCT00124527</DOCNO>
	<brief_summary>Irofulven investigational chemotherapeutic agent study variety solid tumor . The purpose study assess efficacy safety irofulven/capecitabine combination therapy patient anaplastic , medullary , locally advanced/metastatic differentiate thyroid cancer .</brief_summary>
	<brief_title>Study Irofulven Plus Capecitabine Patients With Advanced Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>18 year age old . Cancer thyroid confirm biopsy sample . Specific type thyroid cancer include study anaplastic , differentiate ( papillary , follicular , Hürthle cell ) , medullary thyroid cancer . For patient differentiate ( papillary , follicular , Hürthle cell ) thyroid cancer , 1 prior chemotherapy treatment allow . Measurable disease require ( least one lesion least 2 cm length conventional compute tomography ( CT ) techniques least 1 cm spiral CT scan ) . Any prior chemotherapy radiation therapy must stop least 4 week first dose study treatment . Prior radioiodine ( I131 ) therapy must stop least 3 ( 6 ) month first dose study treatment ( depend responsiveness therapy ) . Recovery toxic effect prior chemotherapy , radiation therapy surgery . Patients reproductive potential must use medically acceptable contraceptive method . Women childbearing potential must negative pregnancy test screening . History retinopathy . Serious ongoing medical psychiatric disorder ( determined clinical investigator ) . External beam radiation therapy &gt; 30 % bone marrow time prior study entry . Prior treatment irofulven capecitabine , protract infusion 5fluorouracil ( 5FU ) ( infusion duration great equal 5 day ) fluoropyrimidines . Therapeutic dos coumarin derivative ( warfarin ) 14 day prior receive first dose study treatment study period . Please note : There additional criterion must meet order eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Irofulven , Thyroid Cancer</keyword>
</DOC>